Active Studies

Parkinson's Studies

  • PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI)

    The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort.

  • Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTs

    Longitudinal evaluation of [18F] AV-133 as a PET radioligand for detecting disease progression in patients with Parkinson disease.

  • A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

    A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease

  • Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's

    A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson’s Disease.

  • Assessment of Brain Tau Burden in Participants With Parkinson's Disease in the PPMI Study

    The Assessment of Brain Tau Burden in Participants with Parkinson's Disease in the PPMI Study (PPMI Tau PET Imaging) will evaluate if [18F] PI-2620 facilitates better understanding of Tau deposition in the brain in Parkinson's disease (PD). 

  • Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's

    A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with a 52 Week Blinded Extension (Pasadena)

Alzheimer's Studies

  • A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

    Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease

  • A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

    A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Diseas

  • A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease

    Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 

  • A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

    A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy, and safety study of MTAU9937A in patients with moderate Alzheimer’s Disease.

Healthy Volunteer Studies

  • PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI)- Healthy Volunteers

    The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study sponsored by the Michael J Fox Foundation to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls 

  • Brain Imaging Studies for Healthy Volunteers

    Many of the symptoms in Alzheimer disease and Parkinson disease relate to changes in specific neurochemicals in the brain. The imaging research program at IND is developing techniques to all for imaging these neurochemical changes.  Healthy volunteers are critical to this research as it is necessary to compare the changes in the brain that occur with the brain of healthy individuals.

Huntington’s Disease

No Active Studies At This Time

ClinicalTrials.gov

www.ClinicalTrials.gov  is a government sponsored website which provides listings of clinical research studies for all diseases, and gives contact information.  You can find the most update-to-date information on IND studies using the link below.